Atyr Pharma INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
ATYR
Atyr Pharma INCaTyr Pharma announced that its lead candidate, efzofitimod, failed to meet its primary endpoint in the Phase 3 EFZO-FIT study for pulmonary sarcoidosis, though secondary endpoints showed clinical improvements.
NASDAQ
ATYR
Atyr Pharma INC10-K: aTyr Pharma Reports Full Year 2024 Results, Highlights Progress in Efzofitimod Clinical Trials
aTyr Pharma's 10-K filing summarizes the company's financial results for 2024 and provides an update on the clinical development of its lead drug candidate, efzofitimod, for interstitial lung diseases.
NASDAQ
ATYR
Atyr Pharma INCaTyr Pharma's 10-K filing outlines the structure of its common stock, preferred stock authorization, and various provisions designed to protect the company from hostile takeovers, while also detailing its clinical programs and regulatory landscape.